MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
663.46%
Quick Ratio
639.59%
Cash Ratio
226.67%
Debt to Asset Ratio
28.66%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term investments
    • Cash and cash equivalents
    • Less accumulated depreciation
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Warrant liabilities
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
56,229
61,374
78,437
82,884
Short-term investments
90,597
106,897
112,967
124,233
Accounts receivable, net
9,394
6,200
6,147
-
Restricted cash
-
-
-
338
Inventory
5,921
6,054
5,493
4,850
Other receivables
495
509
568
1,616
Prepaid expenses and other current assets
1,942
1,951
1,294
2,209
Total current assets
164,578
182,985
204,906
216,130
Total property and equipment, cost
28,725
28,472
27,139
26,694
Less accumulated depreciation
18,573
17,908
17,218
16,356
Property and equipment, net
10,152
10,564
9,921
10,338
Operating lease right-of-use assets
3,950
4,118
3,962
4,086
Other assets
827
827
781
541
Total assets
179,507
198,494
219,570
231,095
Accounts payable
2,994
4,071
7,889
5,927
Accrued expenses
7,197
5,368
8,467
6,888
Current portion of long-term debt
13,333
13,333
12,222
8,889
Current portion of operating lease liability
1,280
1,272
864
102
Payable to licensor
-
7,000
-
-
Accrued taxes and other current liabilities
2
2
126
339
Other current liabilities
-
-
2
35
Total current liabilities
24,806
31,046
29,570
22,180
Long-term operating lease liabilities
3,604
3,814
4,069
4,254
Long-term debt
1,655
4,754
7,813
10,862
Deferred revenue
677
425
-
-
Warrant liabilities
20,707
13,516
18,902
22,566
Total liabilities
51,449
53,555
60,354
59,862
Common stock - 0.01 par value authorized 200,000,000 shares 57,225,919 and 55,043,413 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
572
568
550
524
Additional paid-in capital
906,906
903,542
900,603
892,314
Accumulated deficit
-779,341
-759,150
-742,075
-721,615
Accumulated other comprehensive (loss) income
-79
-21
138
10
Total stockholders equity
128,058
144,939
159,216
171,233
Total liabilities and stockholders equity
179,507
198,494
219,570
231,095
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$90,597K (46.16%↑ Y/Y)Cash and cashequivalents$56,229K (-65.62%↓ Y/Y)Accounts receivable, net$9,394K Inventory$5,921K (120.44%↑ Y/Y)Prepaid expenses andother current assets$1,942K (-7.08%↓ Y/Y)Other receivables$495K (-69.63%↓ Y/Y)Total property andequipment, cost$28,725K (12.44%↑ Y/Y)Total current assets$164,578K (-29.14%↓ Y/Y)Property and equipment,net$10,152K (6.99%↑ Y/Y)Operating leaseright-of-use assets$3,950K (-4.68%↓ Y/Y)Other assets$827K (144.67%↑ Y/Y)Less accumulateddepreciation$18,573K (15.66%↑ Y/Y)Total assets$179,507K (-27.10%↓ Y/Y)Total liabilities andstockholders equity$179,507K (-27.10%↓ Y/Y)Total stockholdersequity$128,058K (-21.71%↓ Y/Y)Total liabilities$51,449K (-37.76%↓ Y/Y)Accumulated deficit-$779,341K (-8.78%↓ Y/Y)Accumulated othercomprehensive (loss) income-$79K (-75.56%↓ Y/Y)Additional paid-in capital$906,906K (3.11%↑ Y/Y)Total currentliabilities$24,806K (-28.13%↓ Y/Y)Warrant liabilities$20,707K (-31.34%↓ Y/Y)Long-term operating leaseliabilities$3,604K (-9.40%↓ Y/Y)Long-term debt$1,655K (-88.18%↓ Y/Y)Deferred revenue$677K Common stock - 0.01 parvalue authorized...$572K (11.72%↑ Y/Y)Current portion oflong-term debt$13,333K (339.97%↑ Y/Y)Accrued expenses$7,197K (30.97%↑ Y/Y)Accounts payable$2,994K (-59.19%↓ Y/Y)Current portion ofoperating lease liability$1,280K (138.36%↑ Y/Y)Accrued taxes and othercurrent liabilities$2K (-99.99%↓ Y/Y)

ABEONA THERAPEUTICS INC. (ABEO)

ABEONA THERAPEUTICS INC. (ABEO)